Linda Yaccarino’s experience will be instrumental in developing innovative programs focusing on the future of peptide ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Jefferies has upgraded its rating to 'hold' from 'underperform' and hiked the target price to Rs 1,950 from Rs 1,350.

Indian pharmaceutical companies are preparing to launch generic versions of Novo Nordisk's weight-loss drug, semaglutide, potentially reducing its price by up to 80%.

Ascletis completes enrollment in US phase IIa study of small molecule oral GLP-1R agonist, ASC30 to treat obesity: Hong Kong Wednesday, August 6, 2025, 10:00 Hrs [IST] Ascletis Ph ...

The Milwaukee Bucks Health and Wellness program is celebrating its one-year anniversary. The free medical program was ...

Linda Yaccarino, the former X CEO who left the social media company in the wake of yet another Elon Musk controversy, has ...

Weight loss and diabetes drugs on the market often do not achieve long-term weight loss for patients. GLP-1 drugs target ...

The post, at the company that focuses on care for GLP-1 users, comes after Yaccarino left Elon Musk's X in July.

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...

Former X CEO Linda Yaccarino said Tuesday she has taken on a new role leading a digital health platform, less than a month ...

Dale Forrest said he wanted to lose weight "naturally" — and a year after starting his weight loss journey, he “can now play ...